IDEXX Launches First Dual-Species Cardiac Test for Pets — IDEXX Laboratories, Inc.

Event summary

IDEXX Laboratories launched the Catalyst™ proBNP Test, the first dual-species point-of-care NT-proBNP test for cardiac disease in pets.
The test is available on IDEXX's Catalyst platform, which has nearly 80,000 analyzers installed globally.
Catalyst proBNP provides results in minutes, enabling real-time cardiac assessment during patient visits.
The test will be available in North America starting October 2026, with international rollout to follow.

The big picture

IDEXX's Catalyst proBNP Test addresses a significant gap in veterinary diagnostics, where cardiac disease affects millions of pets but remains underassessed. The test aligns with the broader trend of point-of-care diagnostics, reducing reliance on referrals and improving early detection. With an installed base of nearly 80,000 analyzers, IDEXX is well-positioned to capture a substantial share of the $4 billion cardiac testing market.

What we're watching

Market Expansion: The pace at which IDEXX can penetrate the $4 billion global cardiac testing opportunity for pets.
Adoption Rate: How quickly veterinarians integrate the Catalyst proBNP Test into routine practice, especially in regions with limited access to cardiology specialists.
Competitive Response: Whether competitors will introduce similar dual-species cardiac tests, potentially disrupting IDEXX's first-mover advantage.